NEW YORK (GenomeWeb) – CombiMatrix is developing two new tests that will expand its place in the reproductive health market, one of which will complement existing chromosomal microarray analysis services and the other of which will open CombiMatrix up to a new market segment.

The company is already benefiting from its focus on prenatal and pediatric CMA services, which drove revenues up 13 percent in the first quarter, and the firm has plans to broaden its offerings in the reproductive health arena, CEO Mark McDonough said on an earnings call.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: Uncovering variants associated with diabetes-related kidney disease, a sequencing study of hepatitis E viruses circulating in Cambodia, and more.

Among Sacks' books was "Awakenings," which was later made into an Academy Award-winning film.

The popularity of the #sciencemoviequote Twitter trend showcases scientists' eclectic movie tastes and knack for puns. 

The popular astrophysicist warned that apathy and even contempt for science in politics could lead to the end of informed democracy.